News – Page 4 – AKL Therapeutics

Phase II osteoarthritis clinical trial underway

The APPA Phase II human trial is being conducted at three sites in Denmark by Nordic Bioscience Clinical Development (NBCD), AKL’s risk share partner, following the successful completion of Phase I. The study is a placebo-controlled, double-blind, randomized trial evaluating the efficacy and safety of oral APPA in 150 patients with osteoarthritis of the knee […]

Abstract published at EULAR 2020

An abstract on a series of uncontrolled patient cases evaluating the efficacy and safety of APPA in patients with osteoarthritis has been published at EULAR 2020 Treatment with APPA was reported as effective by 82.6% of patients, all of whom had failed to have an adequate response with standard prescribed medications. Full abstract is available […]

New research published on APPA’s mode of action

APPA modulates pathological aspects of human neutrophil function, without suppressing antimicrobial ability, and inhibits TNFα expression and signalling A greater understanding of neutrophil biology has led to an appreciation that these cells play a significant role in many systemic inflammatory conditions but targeting neutrophils therapeutically has proven challenging, as host defences must not be compromised. […]

Positive result in APPA Phase I clinical trial

AKL has successfully completed a Phase I APPA in Osteoarthritis (OA) trial. The Principal Investigator of this study summarized in the results that the primary endpoint had been met as “APPA was demonstrated to be safe and well-tolerated by all subjects in the trial”. The full study report will be available shortly. The National Institute […]

Important new evidence on the mode of action of APPA

Previous work has shown that the anti-inflammatory effects seen with APPA results from upregulation of Nrf-2 and reduction of NF-kB activity (see Effects of APPA on Neutrophils). Harmonisation of the molecular cross-talk between these intracellular messengers is known to reduce the levels of COX-1 and COX-2, enzymes that are inhibited by NSAIDs and thought to […]

Former investment banker appointed CFO of AKL

AKL, a company developing an investigational osteoarthritis (OA) medicine, has announced the appointment of Michael Martin as its Chief Financial Officer. With more than 40 years’ global corporate finance experience advising companies in Mergers & Acquisitions, Initial Public Offerings and private equity, Mr Martin brings a wealth of deal experience to the AKL management team. […]